Breaking News Instant updates and real-time market news.

CCRN

Cross Country Healthcare

$11.33

-0.25 (-2.16%)

, CBAY

CymaBay

$13.20

-0.33 (-2.44%)

04:55
03/21/18
03/21
04:55
03/21/18
04:55

Oppenheimer to hold a conference

28th Annual Healthcare Conference will be held in New York on March 20-21.

CCRN

Cross Country Healthcare

$11.33

-0.25 (-2.16%)

CBAY

CymaBay

$13.20

-0.33 (-2.44%)

GLMD

Galmed

$6.29

-0.28 (-4.26%)

SPRO

Spero Therapeutics

$14.23

-0.27 (-1.86%)

GBT

Global Blood Therapeutics

$53.00

-1.15 (-2.12%)

VKTX

Viking Therapeutics

$5.40

0.08 (1.50%)

COLL

Collegium Pharmaceutical

$26.40

-0.68 (-2.51%)

SNSS

Sunesis

$3.33

-0.14 (-4.03%)

VTGN

VistaGen Therapeutics

$1.24

-0.01 (-0.80%)

APTO

Aptose Biosciences

$3.76

0.125 (3.44%)

NLNK

NewLink Genetics

$7.07

0.14 (2.02%)

EVOK

Evoke Pharma

$1.98

-0.08 (-3.88%)

BPMX

BioPharmX

$0.31

0.0465 (17.55%)

MEIP

MEI Pharma

$2.11

0.03 (1.44%)

BLUE

Bluebird Bio

$189.30

-5.65 (-2.90%)

IOVA

Iovance Biotherapeutics

$16.70

0.2 (1.21%)

TNDM

TNDM

LMAT

LeMaitre

$36.90

0.33 (0.90%)

PRTO

Proteon Therapeutics

$2.50

0.1 (4.17%)

SCI

Service Corp.

$38.66

-0.08 (-0.21%)

  • 21

    Mar

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

CCRN Cross Country Healthcare
$11.33

-0.25 (-2.16%)

03/02/18
LSCM
03/02/18
DOWNGRADE
Target $11
LSCM
Hold
Cross Country Healthcare downgraded to Hold from Buy at Lake Street
Lake Street analyst Brooks O'Neil downgraded Cross Country Healthcare to Hold and lowered his price target for the shares to $11 from $16. The analyst is taking a "more conservative approach" following the company's Q4 miss and weaker than expected Q1 outlook. Cantor Fitzgerald this morning also downgraded Cross Country.
03/02/18
CANT
03/02/18
DOWNGRADE
Target $11
CANT
Neutral
Cantor downgrades Cross Country Healthcare to Neutral after 'disappointing' Q4
Cantor Fitzgerald analyst Joseph France downgraded Cross Country Healthcare to Neutral from Overweight and lowered his price target for the shares to $11 from $18. The company reported "disappointing" Q4 results and issued a "soft" Q1 outlook amid challenging volumes and lower daily rates in its Nurse and Allied business, France tells investors in a research note. He believes these trends will persist for some time as hospitals downsize and cut contingent labor spending.
03/01/18
03/01/18
DOWNGRADE

Hold
Cross Country Healthcare downgraded to Hold on growth slowdown at Benchmark
As previously reported, Benchmark analyst Bill Sutherland downgraded Cross Country Healthcare to Hold from Buy following its "surprisingly large" revenue shortfall in Q4 and guidance that was well below his expectation. Sutherland said the Q4 miss appears to be largely about execution, though admits he is also puzzled about the apparent lack of demand, even in the current quarter.
03/02/18
CANT
03/02/18
DOWNGRADE
CANT
Neutral
Cross Country Healthcare downgraded to Neutral from Overweight at Cantor Fitzgerald
CBAY CymaBay
$13.20

-0.33 (-2.44%)

01/25/18
ROTH
01/25/18
INITIATION
Target $27
ROTH
Buy
CymaBay assumed with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi assumed coverage of CymaBay with a Buy rating and $27 price target, noting that while its valuation can stand alone in PBC, NASH is "icing on the cake."
02/13/18
EVER
02/13/18
INITIATION
EVER
Outperform
CymaBay initiated with an Outperform at Evercore ISI
03/19/18
RHCO
03/19/18
NO CHANGE
Target $19
RHCO
Buy
CymaBay price target raised to $19 from $15 at SunTrust
SunTrust analyst Edward Nash raised his price target on CymaBay to $19, saying that 2018 is likely to be a "critical year" for the company given the expected reports of 26-week and 52-week data from Phase 2 trial of seladelpar in primary biliary cholangitis. The analyst adds that a pivotal 2B trial for PBC is expected to be initiated in the second half of this year while also highlighting its clinical need and differentiated profile in the treatment. Nash keeps his Buy rating on CymaBay.
01/24/18
HCWC
01/24/18
NO CHANGE
Target $18
HCWC
Buy
CymaBay price target raised to $18 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay to $18 saying he sees "multiple catalysts" to drive further value creation in 2018. Value should accrue as the seladelpar program matures and expands over next 18 months, Arce tells investors in a research note. He added the company's nonalcoholic steatohepatitis opportunity into his model after meeting with management and reiterates a Buy rating on CymaBay.
GLMD Galmed
$6.29

-0.28 (-4.26%)

03/15/18
MAXM
03/15/18
UPGRADE
MAXM
Buy
Galmed upgraded to Buy from Hold at Maxim
02/15/18
HCWC
02/15/18
NO CHANGE
HCWC
Buy
Galmed selloff yesterday 'way overdone,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce views the selloff yesterday in shares of Galmed Pharmaceuticals is "way overdone." The analyst believes the failed Arrive trial should only carry a minor impact to the shares and sees no negative read throughs to the Arrest study. Arrive was an investigator-initiated trial, conducted at a single site by Professor Rohit Loomba, Acre tells investors in a research note. This was never Galmed's study to begin with, so its failure is not its own, the analyst contends. He remains focused on the Q2 readout of Arrest in NASH patients and keeps a Buy rating on Galmed with a $24 price target.
03/15/18
MAXM
03/15/18
UPGRADE
Target $14
MAXM
Buy
Galmed upgraded to Buy at Maxim on favorable risk-reward
As reported earlier, Maxim analyst James McCarthy upgraded Galmed to Buy from Hold with a price target of $14. McCarthy cites a positive risk/reward heading into the Phase 2b ARREST study of Aramchol at NASH while noting the company's valuation pull-back after the ARRIVE study announced in February for Aramchol vs. placebo in HIV-associated fatty liver disease. The analyst warns that the ARREST study at NASH is a "binary event", and his positive view may be considered "aggressive".
02/15/18
MAXM
02/15/18
DOWNGRADE
MAXM
Hold
Galmed downgraded to Hold at Maxim after failed ARRIVE study
As reported earlier, Maxim analyst Jason McCarthy downgraded Galmed to Hold from Buy after the company's top-line results from ARRIVE phase 2a study did not meet its primary endpoint. The analyst adds however that the failure of Aramchol in HIV patients does not mean it will fail in the upcoming phase 2b ARREST study with 248 NASH patients, noting that the expected outcome from that trial in Q1 will be the next major event for Galmed.
SPRO Spero Therapeutics
$14.23

-0.27 (-1.86%)

11/27/17
11/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. iRadimed (IRMD) initiated with an Outperform at Credit Suisse. 2. Funko (FNKO) was initiated with a Buy at Goldman Sachs, SunTrust, BofA/Merrill, Jefferies, and Stifel, while being initiated with an Overweight at JPMorgan and an Outperform at BMO Capital. 3. Evoqua Water (AQUA) was initiated with an Outperform at RBC Capital and Raymond James, a Buy at Citi, a Hold at Stifel, as well as a Neutral at Goldman Sachs and Baird. 4. Spero Therapeutics (SPRO) was initiated with an Outperform at Oppenheimer and Cowen, a Buy at Stifel, and a Neutral at BofA/Merrill. 5. Altair (ALTR) was initiated with an Outperform at William Blair, a Buy at Deutsche Bank, a Sector Perform at RBC Capital, a Hold at Canaccord, and a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/18
CANT
02/08/18
INITIATION
Target $27
CANT
Overweight
Spero Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Spero Therapeutics with an Overweight and $27 price target.
02/09/18
02/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Motorola Solutions (MSI) initiated with a Neutral at JPMorgan. 2. Spero Therapeutics (SPRO) initiated with an Overweight at Cantor Fitzgerald. 3. County Bancorp (ICBK) initiated with a Neutral at DA Davidson. 4. Diplomat Pharmacy (DPLO) initiated with a Buy at Lake Street. 5. Pulmatrix (PULM) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/17
OPCO
11/27/17
INITIATION
Target $30
OPCO
Outperform
Spero Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started Spero Therapeutics with an Outperform rating and $30 price target based on his view of multiple well-differentiated pipeline assets, two of which he considers relatively de-risked, and further upside potential provided by additional assets.
GBT Global Blood Therapeutics
$53.00

-1.15 (-2.12%)

01/23/18
01/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abeona Therapeutics (ABEO) assumed with an Outperform at RBC Capital. 2. Jack Henry (JKHY) initiated with a Neutral at DA Davidson. 3. Woodward (WWD) re-initiated with a Market Perform at Barrington. 4. Navistar (NAV) initiated with a Neutral at Buckingham. 5. Global Blood Therapeutics (GBT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/18
RHCO
03/01/18
NO CHANGE
Target $80
RHCO
Buy
Global Blood Therapeutics price target raised to $80 from $67 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Global Blood Therapeutics to $80 after the company's Q4 earnings as well as the recent positive interim HOPE data that increased his conviction of a successful readout for GBT440's Phase 3 program. Suneja keeps his Buy rating, noting that while an accelerated approval based on the early efficacy data is possible, the management targets approval for Part B data in the first half of FY19.
02/13/18
JANY
02/13/18
INITIATION
JANY
Buy
Global Blood Therapeutics initiated with a Buy at Janney Capital
02/28/18
CANT
02/28/18
NO CHANGE
Target $72
CANT
Overweight
Global Blood price target raised to $72 from $61 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Global Blood Therapeutics to $72 citing increased confidence going into the Phase 3 Part A study with voxelotor in patients with sickle cell disease. The analyst says that while the company did not host a Q4 earnings conference call, he did not find any surprises in the annual filing. Piros raised his probability of success for the sickle cell disease program to 70% from 55% and reiterates an Overweight rating on Global Blood shares.
VKTX Viking Therapeutics
$5.40

0.08 (1.50%)

11/10/17
HCWC
11/10/17
INITIATION
Target $7
HCWC
Buy
Viking Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Viking Therapeutics with a Buy rating and $7 price target. The analyst views the company as an "underappreciated microcap stock with five novel drugs in the pipeline."
11/21/17
ROTH
11/21/17
INITIATION
Target $5
ROTH
Buy
Viking Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Viking Therapeutics with a Buy rating and $5 price target, citing a favorable risk/reward profile for the company's emerging pipeline.
11/28/17
MAXM
11/28/17
NO CHANGE
Target $8
MAXM
Buy
Viking Therapeutics price target raised to $8 from $5 at Maxim
Maxim analyst Jason McCarthy raised his price target for Viking Therapeutics to $8 after the company announced that the Phase 2 hip fracture study of VK5211 reached statistical significance in the primary endpoint of an increase in lean body mass. The analyst adjusted his risk profile in hip fracture to 25% from 50% with the data exceeding his expectations. McCarthy remains positive on Viking with a Buy rating citing the unmet medical need in hip fracture.
07/17/17
HCWC
07/17/17
NO CHANGE
Target $7
HCWC
Buy
Viking Therapeutics price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Viking Therapeutics to $7 saying the VX5211 hip fracture trial has a high probability of success based on data in primates and healthy volunteers. The analyst has modeled the VX5211 launch in 2021 in the U.S. and 2022 in Europe. She reiterates a Buy rating on Viking.
COLL Collegium Pharmaceutical
$26.40

-0.68 (-2.51%)

02/12/18
PIPR
02/12/18
NO CHANGE
Target $33
PIPR
Overweight
Piper reiterates Overweight on Collegium after Purdue stops marketing opioids
Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Collegium Pharmaceutical with a $33 price target after Purdue Pharma announced that it will no longer promote its opioid products, including OxyContin. Purdue's actions will ultimately make it easier for Collegium to execute on securing additional contracts with payers where Xtampza ER has a position of formulary exclusivity, Amsellem tells investors in a research note.
02/12/18
JEFF
02/12/18
NO CHANGE
Target $32
JEFF
Buy
Collegium Pharmaceutical price target raised to $32 from $27 at Jefferies
Jefferies analyst David Steinberg raised his price target for Collegium Pharmaceutical to $32 saying IMS data show a "strong acceleration" for Xtampza in early 2018. Prescriptions las week increased 7.4% to 4,869, up 67% year-to-date, implying a $75M-plus run rate, Steinberg tells investors in a research note. In more good news for Collegium, Purdue announced this weekend that it will no longer detail OxyContin, the analyst adds. He raised his fiscal 2018 Xtampza sales estimate to $88M and keeps a Buy rating on the shares.
02/07/18
NEED
02/07/18
NO CHANGE
Target $35
NEED
Buy
Collegium Pharmaceutical price target raised to $35 from $28 at Needham
Needham analyst Serge Belanger raised his price target on Collegium Pharmaceutical to $35, citing a strong start to 2018 marked by the closing of the Nucynta licensing agreement and Xtampza Rx growth. Belanger says Nucynta is now being commercialized by the company and is expected to generate FY18 sales of $236M, while Xtampza's inclusion as the exclusive oxycodone ER on numerous prominent payor formularies should raise its FY18 sales to about $75M from prior view of $60M. Belanger keeps his Buy rating on Collegium Pharmaceutical.
03/08/18
HCWC
03/08/18
NO CHANGE
Target $33
HCWC
Buy
Collegium price target raised to $33 from $21 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Collegium Pharmaceutical to $33 following the company's Q4 results. Operational execution is driving continued strong growth of Xtampza ER, Arce tells investors in a post-earnings research note. The analyst sees "significant upside from current levels" and keeps a Buy rating on Collegium shares.
SNSS Sunesis
$3.33

-0.14 (-4.03%)

12/11/17
WELS
12/11/17
UPGRADE
Target $8
WELS
Outperform
Sunesis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Sunesis Pharmaceuticals to Outperform following a review of updated data for novel BTK inhibitor vecabrutinib at the American Society of Hematology meeting. Expert feedback at the meeting suggests vecabrutinib could become treatment of choice for Imbruvica resistance and ultimately a preferred choice over Imbruvica as a frontline treatment in a $3B-plus BTK inhibitor market, Birchenough tells investors in a research note. The analyst expects positive vecabrutinib data despite recent management departures and upped his price target for Sunesis shares to $8 from $2.
12/05/17
CANT
12/05/17
NO CHANGE
Target $3
CANT
Neutral
Sunesis clinical picture unchanged with CEO leaving, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein believes shares of Sunesis Pharmaceuticals could face pressure on the resignation of President and CEO Dan Swisher. The loss, however, is not an indictment of the clinical potential of SNS-062, Goldstein tells investors in a research note. However, the analyst believes the resignation makes it harder for investors to maintain focus on the company without a CEO at the helm, particularly as interim data are not expected until mid-2018. She keeps a Neutral rating on Sunesis with a $3 price target.
12/05/17
WELS
12/05/17
DOWNGRADE
Target $2
WELS
Market Perform
Sunesis downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Sunesis Pharmaceuticals to Market Perform following the resignation of the company's CEO Daniel Swisher. While the executive is pursuing an attractive opportunity at a larger biopharmaceutical company, the move highlights the early stage nature of Sunesis' pipeline, extended timelines for development and potential risk in realizing the potential for lead BTK inhibitor SNS062, Birchenough tells investors in a research note. The analyst cut his price target for the shares to $2 from $5.
11/21/17
11/21/17
INITIATION
Target $7

Outperform
Oppenheimer says Sunesis has defined opportunity, initiates with Outperform
As previously reported, Oppenheimer analyst Hartaj Singh started Sunesis (SNSS) with an Outperform rating and $7 price target. While AbbVie's (ABBV) ibrutinib has demonstrated a robust risk/benefit profile across many tumor types, it is becoming apparent that about 10% or more of leukemia and lymphoma patients have a mutation that leads to relapse on ibrutinib, he contends. The analyst believes Sunesis' reversible and potent BTK inhibitor SNS-062 has the ability to address this patient population, both upon relapse following ibrutinib or directly through a biomarker-driven approach.
VTGN VistaGen Therapeutics
$1.24

-0.01 (-0.80%)

03/28/17
MAXM
03/28/17
INITIATION
Target $4
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
Maxim analyst Lauren Chung initiated VistaGen with a Buy rating and $4 price target, based on the opportunity for the company's AV-101, which is part of an emerging class of antidepressant drugs with the potential for rapid relief of depressive symptoms. VistaGen is now in a Phase 2 study that will help establish the safety profile for AV-101 and is designing a Phase 2 adjunctive therapy study that is expected to initiate in 2H17, Chung noted.
APTO Aptose Biosciences
$3.76

0.125 (3.44%)

10/23/17
ROTH
10/23/17
INITIATION
Target $5
ROTH
Buy
Aptose Biosciences resumed with a Buy at Roth Capital
Roth Capital analyst Jotin Marango resumed Aptose Biosciences with a Buy rating and $5 price target as he sees fundamental value discounted due to formulation and manufacturing mishaps.
09/07/17
HCWC
09/07/17
UPGRADE
Target $4
HCWC
Buy
Aptose Biosciences upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis upgraded Aptose Biosciences to Buy and raised his price target for the shares to $4 from $1. Having finalized manufacturing for CG'806 in a timely manner, Aptose can now further solidify its projected timeline for getting the drug into the clinic, Pantginis tells investors in a research note. The analyst increased his projected chance of success for CG'806 to 7% from 5%.
06/08/17
RODM
06/08/17
INITIATION
Target $1
RODM
Neutral
Aptose Biosciences initiated with a Neutral at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Aptose Biosciences with a Neutral rating and $1.00 price target. The analyst sees a lack of meaningful catalysts for the remainder of 2017.
12/13/17
HCWC
12/13/17
NO CHANGE
Target $6
HCWC
Buy
Aptose Biosciences price target raised to $6 from $4 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Aptose Biosciences to $6 saying the company's collaborators at the American Society of Hematology annual meeting presented a broad set of preclinical data, which provides a "nice boost" to the profile of CG'806. The analyst keeps a Buy rating on Aptose.
NLNK NewLink Genetics
$7.07

0.14 (2.02%)

01/08/18
STFL
01/08/18
NO CHANGE
STFL
Buy
NewLink Genetics timelines mostly in-line with prior guidance, says Stifel
Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
03/02/18
STFL
03/02/18
NO CHANGE
Target $21
STFL
Buy
NewLink Genetics price target lowered to $21 from $25 at Stifel
Stifel analyst Stephen Willey said NewLink Genetics' approximately 2-month delay in starting patient enrollment into the randomized portion of the Phase 3 Indigo301 trial is an incremental negative, but noted that management remains confident in its ability to implement the "fundamentally-simple changes" needed and the delay may actually provide increased flexibility in terms of strategically pivoting off Phase 3 ECHO-301 data. He has "conservatively" pushed-out indoximod launch timelines and lowered his price target on NewLink shares to $21 from $25, but maintains a Buy rating on the stock.
EVOK Evoke Pharma
$1.98

-0.08 (-3.88%)

10/06/17
GHSC
10/06/17
INITIATION
Target $10
GHSC
Buy
Evoke Pharma initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Evoke Pharma with a Buy and $10 price target saying it has a clear regulatory path for advancing Gimoti as a metoclopramide nasal spray treatment for acute and recurrent gastroparesis in women with diabetes mellitus.
10/19/17
10/19/17
INITIATION
Target $10

Buy
Evoke Pharma reinstated with a Buy at FBR Capital
FBR Capital analyst David Buck reinstated coverage of Evoke Pharma with a Buy rating and $10 price target.
BPMX BioPharmX
$0.31

0.0465 (17.55%)

09/13/17
HCWC
09/13/17
NO CHANGE
Target $3
HCWC
Buy
BioPharmX early rosacea study results promising, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth views BioPharmX's early results from the BPX-01 rosacea study as promising. The results suggest that BPX-01 could become a "safe and highly effective therapy against rosacea," Ramakanth tells investors in a research note. The analyst reiterates a Buy rating on the shares with a $3 price target.
MEIP MEI Pharma
$2.11

0.03 (1.44%)

05/24/17
OPCO
05/24/17
INITIATION
Target $6.5
OPCO
Outperform
MEI Pharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started MEI Pharma with an Outperform rating and $6.50 price target, estimating that two of the company's three experimental compounds, namely Pracinostat and MEI-401, could result in sales in 2022. Pracinostat could result in calendar 2023 product sales of about $704M and royalty income to MEI of nearly $127M, while MEI-401 could yield CY2023 sales to the company of about $621M, the analyst noted.
BLUE Bluebird Bio
$189.30

-5.65 (-2.90%)

03/05/18
WBLR
03/05/18
INITIATION
WBLR
Outperform
bluebird bio initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started bluebird bio with an Outperform rating and $242 fair value estimate. Management is executing well on becoming a company with two-plus products on the market, two-plus programs nearing commercialization, and four-plus additional programs by 2022, Prasad tells investors in a research note titled "Suit Up! 2018 Could Be Another Blue-Ribbon Year." The analyst sees this year's catalysts centering around three medical conferences which he thinks have the potential to enhance bluebird bio's status as a leading innovator in cell and gene therapies.
03/16/18
03/16/18
INITIATION

Bluebird Bio initiated with a Sell at Favus
03/14/18
JANY
03/14/18
INITIATION
Target $220
JANY
Neutral
Bluebird Bio initiated with a Neutral at Janney Capital
Janney Capital initiated Bluebird Bio with a Neutral rating and $220 fair value estimate.Target $220.
03/08/18
BTIG
03/08/18
NO CHANGE
Target $250
BTIG
Buy
Bluebird Bio price target raised to $250 from $177 at BTIG
BTIG analyst Dane Leone raised his price target for Bluebird Bio to $250 to reflect recent acquisitions of peer companies, meetings with the management team, and conversations at the American Society for Blood and Marrow Transplantation conference. Following the acquisition of Juno, Bluebird stands as the leading independent company with integrated genetic and cell therapy capabilities, Leone tells investors in a research note. He believes, however, that Bluebird management has no interest in selling the company within the near term. The analyst says his new price target reflects the company's long-term value proposition. Leone keeps a Buy rating on Bluebird Bio.
IOVA Iovance Biotherapeutics
$16.70

0.2 (1.21%)

03/13/18
RILY
03/13/18
NO CHANGE
Target $22
RILY
Neutral
Iovance price target raised to $22 from $18.50 at B. Riley FBR
B. Riley FBR analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $22 following the company's Q4 results. The analyst remains long-term positive on TIL technology in immuno-oncology, but says the absence of clinical catalysts and the stock's year-to-date share performance temper his enthusiasm near-term. He reiterates a Neutral rating on Iovance.
02/23/18
RILY
02/23/18
DOWNGRADE
Target $18.5
RILY
Neutral
Iovance downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar downgraded Iovance Biotherapeutics to Neutral while raising his price target for the shares to $18.50 from $18. The downgrade follows the recent move higher in the shares.
02/09/18
JEFF
02/09/18
NO CHANGE
Target $31
JEFF
Buy
Iovance Biotherapeutics price target raised to $31 from $11 at Jefferies
Jefferies analyst Biren Amin raised his price target for Iovance Biotherapeutics to $31 saying the FDA is likely to agree to the company's proposal to run a Phase II trial in refractory melanoma using less stringent endpoints such as response rates and duration of response versus overall survival. He believes LN-144 could provide a "compelling option for patients refractory to IO therapies." The analyst now includes estimates for the head and neck cancer indication where he added risk-adjusted peak U.S. revenue of $334M citing "early encouraging data." Amin keeps a Buy rating on Iovance.
03/13/18
JEFF
03/13/18
NO CHANGE
Target $31
JEFF
Buy
Iovance data updates in 2018 should drive further upside, says Jefferies
Iovance Biotherapeutics last night provided an update on four ongoing clinical programs and its regulatory strategy for the melanoma program, Jefferies analyst Biren Amin writes in a post-earnings research note. Iovance continues to have an ongoing FDA dialogue and it is possible the company may be allowed to expand the current trial, the analyst adds. He sees the company's updates from Phase II melanoma, head and neck, and/or cervical studies in 2018 providing further share upside. Amin keeps a Buy rating on Iovance with a $31 price target.
TNDM TNDM

02/27/18
OPCO
02/27/18
INITIATION
Target $5.5
OPCO
Outperform
Tandem Diabetes initiated with an Outperform at Oppenheimer
Oppenheimer analyst Steven Lichtman started Tandem Diabetes with an Outperform rating and $5.50 price target, citing new opportunities ahead.
01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
02/15/18
PIPR
02/15/18
NO CHANGE
PIPR
Tandem's financing, study data both positive signs, says Piper Jaffray
Piper Jaffray analyst JP McKim said he is becoming more positive on Tandem Diabetes since its most recent round of financing removes its liquidity risk, and its PROLOG study data showed a 31% reduction in hypo readings without increasing hyper readings. However McKim maintained a Neutral rating on Tandem Diabetes shares, saying he needs to see another quarter of solid pump sales to become more constructive on the stock.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
LMAT LeMaitre
$36.90

0.33 (0.90%)

02/22/18
BRRR
02/22/18
NO CHANGE
BRRR
LeMaitre earnings, guidance solid, says Barrington
Barrington analyst Michael Petusky maintained a Market Perform rating on LeMaitre shares, saying while the company reported a solid Q4, exceeding the firm's estimate on the bottom line, increased its dividend 27.3%, and guided for a solid FY18, it remains difficult to gauge valuation, and Petusky would reconsider if the event of non-fundamental share weakness.
10/27/17
FANA
10/27/17
DOWNGRADE
FANA
Equal-Weight
LeMaitre downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Joseph Munda downgraded LeMaitre Vascular to Equal-Weight citing valuation following the company's Q3 results. The analyst believes the company's fundamentals remain attractive and keeps a $34 price target for the shares.
10/27/17
10/27/17
DOWNGRADE

Hold
LeMaitre downgraded to Hold on slowing growth at Benchmark
As previously reported, Benchmark analyst Raymond Myers downgraded LeMaitre (LMAT) to Hold from Buy noting that is growth has slowed from its prior "unsustainable" pace and he sees some operational challenges. In the wake of the "unexpected" mid-2016 support from Baxter's (BAX) competitive recall, he anticipates tougher 2017 comparisons, he tells investors.
10/27/17
BNCH
10/27/17
DOWNGRADE
BNCH
Hold
LeMaitre downgraded to Hold from Buy at Benchmark
PRTO Proteon Therapeutics
$2.50

0.1 (4.17%)

SCI Service Corp.
$38.66

-0.08 (-0.21%)

08/18/17
OPCO
08/18/17
NO CHANGE
Target $39
OPCO
Outperform
Service Corp. target raised to $39 on sales momentum at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for Service Corp. to $39 from $37 saying he expects continued business momentum via Cemetery pre-need sales growth. The company is effectively leveraging its size and scale as the leader within the sizable $19B deathcare industry, Schneeberger tells investors in a research note. He reiterates an Outperform rating on the shares.
11/03/17
FBCO
11/03/17
INITIATION
Target $40
FBCO
Outperform
Service Corp. assumed with an Outperform at Credit Suisse
Credit Suisse analyst A.J. Rice assumed coverage of Service Corp. with an Outperform rating and increased price target of $40.
02/05/18
FBCO
02/05/18
NO CHANGE
Target $46
FBCO
Outperform
Service Corp. price target raised to $46 from $40 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Service Corp. to $46 from $40 ahead of quarterly results, while noting that death and taxes are still certain, but taxes will be less onerous in 2018. The analyst reiterates an Outperform rating on the shares.
12/15/17
12/15/17
NO CHANGE

Service Corp. initiated with a Sell recommendation at Off Wall Street

TODAY'S FREE FLY STORIES

FIT

Fitbit

$5.93

0.22 (3.86%)

15:00
08/20/18
08/20
15:00
08/20/18
15:00
Options
Fitbit calls active as shares extend gains »

Fitbit calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

MMM

3M

$204.54

-0.27 (-0.13%)

, SGMS

Scientific Games

$30.45

0.85 (2.87%)

14:53
08/20/18
08/20
14:53
08/20/18
14:53
Hot Stocks
3M announces filing of touch screen technology patent infringement lawsuit »

3M (MMM) and 3M…

MMM

3M

$204.54

-0.27 (-0.13%)

SGMS

Scientific Games

$30.45

0.85 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPY

Brookfield Property

$19.94

-0.15 (-0.75%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Conference/Events
Brookfield Property management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

LCI

Lannett

$5.40

-8.1 (-60.00%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

AABA

Altaba

$69.92

1.74 (2.55%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Options
Altaba Inc options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$20.26

0.31 (1.55%)

14:47
08/20/18
08/20
14:47
08/20/18
14:47
Conference/Events
Summit Materials management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

, ANDV

Andeavor

$147.76

2.82 (1.95%)

14:46
08/20/18
08/20
14:46
08/20/18
14:46
Hot Stocks
FTC approves Alimentation Couche-Tard sale of two Minnesota fuel stations »

The Federal Trade…

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

ANDV

Andeavor

$147.76

2.82 (1.95%)

ANCUF

Alimentation Couche-Tard

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$15.94

0.61 (3.98%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHII

PHI, Inc

$8.59

0.09 (1.06%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Hot Stocks
Alesia Value fund reports 4.7% stake in PHI »

On August 20,Alesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$216.05

-1.6 (-0.74%)

14:41
08/20/18
08/20
14:41
08/20/18
14:41
Periodicals
Breaking Periodicals news story on Apple »

Apple planning revamped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHVF

MGM China

$0.00

(0.00%)

14:36
08/20/18
08/20
14:36
08/20/18
14:36
Upgrade
MGM China rating change  »

MGM China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
The Fed has become an unexpected focus »

The Fed has become an…

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
Canada wholesale preview »

Canada wholesale preview:…

CTWS

Connecticut Water

$69.10

0.1 (0.14%)

14:34
08/20/18
08/20
14:34
08/20/18
14:34
Hot Stocks
PURA approves rate settlement agreement for Connecticut Water »

Connecticut Water Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$30.38

-0.095 (-0.31%)

14:30
08/20/18
08/20
14:30
08/20/18
14:30
Conference/Events
Williams management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

AMZN

Amazon.com

$1,880.70

-1.24 (-0.07%)

14:29
08/20/18
08/20
14:29
08/20/18
14:29
Periodicals
Amazon hires well-known cardiologist amid push into health, CNBC says »

Amazon has hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AMCX

AMC Networks

$61.70

1.28 (2.12%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
AMC Networks management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

OSPR

Osprey Energy Acquisition

$11.27

0.065 (0.58%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
Osprey Energy Acquisition to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PPG

PPG

$109.64

1.23 (1.13%)

14:24
08/20/18
08/20
14:24
08/20/18
14:24
Conference/Events
PPG management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

NFLX

Netflix

$330.55

13.77 (4.35%)

14:21
08/20/18
08/20
14:21
08/20/18
14:21
Technical Analysis
Technical Take: Netflix may test downtrend resistance line »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/20/18
08/20
14:17
08/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$5.35

-8.15 (-60.37%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

MBI

MBIA

$10.78

-0.22 (-2.00%)

14:15
08/20/18
08/20
14:15
08/20/18
14:15
Options
MBIA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$30.79

0.05 (0.16%)

14:08
08/20/18
08/20
14:08
08/20/18
14:08
Hot Stocks
SEC says Merrill Lynch to pay $8.9M to settle charges of undisclosed conflict »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.